Integrated Biosciences Raises $17 Million to Accelerate Development of Drugs Targeting Age-Related Diseases

Sutter Hill Ventures-led round will accelerate drug pipeline development and advance commercialization efforts, bringing science a step closer to targeting aging

Excerpt from the Press Release:

REDWOOD CITY, Calif.–(BUSINESS WIRE)–Integrated Biosciences, a biotechnology company pioneering the use of synthetic biology and machine learning to develop next-generation therapeutics for age-related diseases, today announced that it has closed a $17.2 million seed financing, led by Sutter Hill Ventures with participation from Root Ventures, Civilization Ventures, Illumina Ventures Labs, Lifespan Vision Ventures, Overlap Holdings, SH Fund (Sabrina Hahn), Conscience VC, Mission BioCapital, Reinforced Ventures, Polymath Capital, Michael Stoppelman, and Vijay Pandurangan. The company also announced that Keith Loebner, Ph.D. has been appointed to the company’s Board of Directors and that Karl Sylvester, M.D., Uri Alon, Ph.D., and Wendy B. Young, Ph.D. have been appointed as advisors to the company.

“We started Integrated Biosciences to make real progress toward achieving healthier human aging,” said Felix Wong, Ph.D., Co-Founder and CEO. “The new capital will significantly advance our efforts toward this ambitious goal by enabling us to scale up our synthetic biology and AI platform while investing in the clinical development of our small-molecule portfolio. Our world-class syndicate, led by Sutter Hill Ventures, represents visionary investors who appreciate our scientific progress and understand that we are an entirely different type of company, in terms of both our mission and our technology.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release